Cite

HARVARD Citation

    Weishaupt, C. et al. (2016). Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet. 3 (2), pp. e72-e79. [Online]. 
  
Back to record